3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Myeloid
2
Classical hematology
2
Conditions
beta-Thalassemia
2
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Anemia
2
Primary Myelofibrosis
1
Higher-risk Myelodysplastic Syndrome
1
Interventions
Epoetin Alfa
27
Darbepoetin alfa
13
epoetin beta
3
Erythropoietin
3
telapristone acetate
2
luspatercept
2
ferric carboxymaltose
2
Lenalidomide
2
Ferric Oxide, Saccharated
2
Cisplatin
2
Blood Transfusion
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
ibrutinib
1
fludarabine phosphate
1
fludarabine
1
ferrous sulfate
1
ferric gluconate
1
ferric derisomaltose
1
fanasil, pyrimethamine drug combination
1
Taxes
1
Sugars
1
Sucrose
1
Solutions
1
Saline Solution
1
Rituximab
1
Radiotherapy
1
Pharmacogenomic Testing
1
Paclitaxel
1
Iron-Dextran Complex
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Anemia
×
luspatercept
×
Clear all
NCT04717414
2025-07-10
INDEPENDENCE
Celgene
Phase 3
Active not recruiting
313 enrolled
NCT02631070
2021-12-17
MEDALIST
Celgene
Phase 3
Completed
229 enrolled
36 charts
1 FDA